https://mbcbiolabs.com/wp-content/uploads/2025/02/ArdaTherapeutics.pngTarget cells, not pathwaysArda Therapeutics is developing therapeutics to eliminate pathogenic cells that drive chronic diseases and aging. Using a cutting-edge single-cell discovery engine, Arda identifies these harmful cells and the specific markers that distinguish them. This precision enables the development of entirely novel therapeutics tailored to eradicate these cell populations, employing advanced modalities developed for immuno-oncology and now reimagined for chronic disease. Guided by the vision of restoring harmony within the body, Arda is initially focused on fibrotic and inflammatory diseases while building a diverse pipeline of therapies unified by the strategy of selective cell elimination.Website → Our Speaker https://mbcbiolabs.com/wp-content/uploads/2025/02/AdamFreund.jpg Dr. Adam Freund Dr. Freund is the founder and CEO of Arda Therapeutics, with over two decades of experience in life science R&D. As a former Principal Investigator at Calico, Dr. Freund established and directed a lab dedicated to enhancing healthspan through advanced quantification methodologies and interventions that included small molecules, large molecules, gene and cell therapy, and dietary modulation. He launched and led several therapeutic programs, notably spearheading Calico’s first program targeting a validated longevity pathway, which is now advancing in clinical trials. Dr. Freund earned his PhD from UC Berkeley, where he explored cellular senescence mechanisms, followed [...]